These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required
on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic
environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or
reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant
further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange
impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Recalling the concern reflected in the outcome document of the United Nations Conference
on Sustainable Development, entitled «The future we want», 1 that the health of oceans and marine biodiversity are negatively affected by marine pollution, including marine debris, especially plastic, persistent organic pollutants, heavy metals and nitrogen - based compounds, from numerous marine and land - based sources, and the commitment to take action to significantly
reduce the incidence and
impacts of such pollution
on marine ecosystems, Noting the international action being taken to promote the sound management of chemicals throughout their life cycle and waste in ways that lead to the prevention and minimization of significant adverse effects
on human health and the
environment, Recalling the Manila Declaration on Furthering the Implementation of the Global Programme of Action for the Protection of the Marine Environment from Land - based Activities adopted by the Third Intergovernmental Review Meeting on the Implementation of the Global Programme of Action for the Protection of the Marine Environment from Land - based Activities, which highlighted the relevance of the Honolulu Strategy and the Honolulu Commitment and recommended the establishment of a global partnership on marine litter, Taking note of the decisions adopted by the eleventh Conference of the Parties to the Convention on Biological Diversity on addressing the impacts of marine debris on marine and coastal biodiversity, Recalling that the General Assembly declared 2014 the International Year of Small Island Developing States and that such States have identified waste management among their priorities for action, Noting with concern the serious impact which marine litter, including plastics stemming from land and sea - based sources, can have on the marine environment, marine ecosystem services, marine natural resources, fisheries, tourism and the economy, as well as the potential risks to human
environment, Recalling the Manila Declaration
on Furthering the Implementation of the Global Programme of Action for the Protection of the Marine
Environment from Land - based Activities adopted by the Third Intergovernmental Review Meeting on the Implementation of the Global Programme of Action for the Protection of the Marine Environment from Land - based Activities, which highlighted the relevance of the Honolulu Strategy and the Honolulu Commitment and recommended the establishment of a global partnership on marine litter, Taking note of the decisions adopted by the eleventh Conference of the Parties to the Convention on Biological Diversity on addressing the impacts of marine debris on marine and coastal biodiversity, Recalling that the General Assembly declared 2014 the International Year of Small Island Developing States and that such States have identified waste management among their priorities for action, Noting with concern the serious impact which marine litter, including plastics stemming from land and sea - based sources, can have on the marine environment, marine ecosystem services, marine natural resources, fisheries, tourism and the economy, as well as the potential risks to human
Environment from Land - based Activities adopted by the Third Intergovernmental Review Meeting
on the Implementation of the Global Programme of Action for the Protection of the Marine
Environment from Land - based Activities, which highlighted the relevance of the Honolulu Strategy and the Honolulu Commitment and recommended the establishment of a global partnership on marine litter, Taking note of the decisions adopted by the eleventh Conference of the Parties to the Convention on Biological Diversity on addressing the impacts of marine debris on marine and coastal biodiversity, Recalling that the General Assembly declared 2014 the International Year of Small Island Developing States and that such States have identified waste management among their priorities for action, Noting with concern the serious impact which marine litter, including plastics stemming from land and sea - based sources, can have on the marine environment, marine ecosystem services, marine natural resources, fisheries, tourism and the economy, as well as the potential risks to human
Environment from Land - based Activities, which highlighted the relevance of the Honolulu Strategy and the Honolulu Commitment and recommended the establishment of a global partnership
on marine litter, Taking note of the decisions adopted by the eleventh Conference of the Parties to the Convention
on Biological Diversity
on addressing the
impacts of marine debris
on marine and coastal biodiversity, Recalling that the General Assembly declared 2014 the International Year of Small Island Developing States and that such States have identified waste management among their priorities for action, Noting with concern the serious
impact which marine litter, including plastics stemming from land and sea - based sources, can have
on the marine
environment, marine ecosystem services, marine natural resources, fisheries, tourism and the economy, as well as the potential risks to human
environment, marine ecosystem services, marine natural resources, fisheries, tourism and the economy, as well as the potential risks to human health; 1.